Probiotics have role in management of infant colic, suggest trial results

Published On 2019-12-05 13:45 GMT   |   Update On 2019-12-05 13:45 GMT

Infant colic is a very common gastrointestinal disorder affecting up to 25% of infants in the first 3 months of life, and although it is a benign condition, it is a source of major distress for the infants and their families. It is a cause of maternal postpartum depression, early breastfeeding cessation, formula changes, and long-term adverse outcomes such as allergies and behaviour and sleep problems. There is no specific treatment of infant colic available.


The pathogenesis of infant colic is poorly defined and it is presumed that gut microbiota may be involved, supporting the potential therapeutic role of probiotics in infant colic.

Probiotics--or "good bacteria"--have been used to treat infant colic with varying success. In a new trial published in the journal Alimentary Pharmacology & Therapeutics, investigators have shown that drops containing a particular probiotic strain (Bifidobacterium animalis subsp. lactis BB-12) reduced the duration of daily crying by more than 50% in 80% of the 40 infants who received the probiotic once daily for 28 days, with beneficial effects on sleep duration and on stool frequency and consistency. This compared with only 32.5% of the 40 infants who received a placebo.


Please also read-Study finds no role of Probiotics in acute gastroenteritis in children

The effect seen in the study was associated with a positive modulation of the gut microbiome, with increased bacterial production of butyrate, a short-chain fatty acid that is able to positively regulate intestinal transit time, pain perception, the gut-brain axis, and inflammation.


"Our study provides evidence on the important role of the gut microbiota as a target of intervention against infant colic," said senior author Roberto Berni Canani, MD, PhD of the University of Naples "Federico II," in Italy. "It is relevant to underline that this trial studied a specific well-characterized probiotic strain and that these findings cannot be extrapolated for other probiotic strains."


Alimentary Pharmacology & Therapeutics

For more details click on the link: http://dx.doi.org/10.1111/apt.15561
Article Source : Alimentary Pharmacology & Therapeutics

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News